Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
(CH3)2CHOH
CAS Number:
Molecular Weight:
60.10
EC Number:
200-661-7
UNSPSC Code:
12352001
PubChem Substance ID:
Beilstein/REAXYS Number:
635639
MDL number:
Assay:
≥99.7%
Bp:
82 °C (lit.)
Vapor pressure:
44 mmHg ( 25 °C), 33 mmHg ( 20 °C)
agency
JIS 1000
vapor density
2.1 (vs air)
vapor pressure
44 mmHg ( 25 °C), 33 mmHg ( 20 °C)
assay
≥99.7%
form
liquid
autoignition temp.
750 °F
expl. lim.
2.0-12.7 %, 93 °C
availability
available only in Japan
dilution
(for analytical testing)
refractive index
n20/D 1.377 (lit.)
bp
82 °C (lit.)
mp
−89.5 °C (lit.)
density
0.785 g/mL at 25 °C (lit.)
suitability
suitable for residue analysis
SMILES string
CC(C)O
InChI
1S/C3H8O/c1-3(2)4/h3-4H,1-2H3
InChI key
KFZMGEQAYNKOFK-UHFFFAOYSA-N
Still not finding the right product?
Explore all of our products under 2-Propanol
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
3 - Flammable liquids
wgk
WGK 1
flash_point_f
53.6 °F - closed cup
flash_point_c
12.0 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Peter C Grayson et al.
Arthritis & rheumatology (Hoboken, N.J.), 67(7), 1922-1932 (2015-04-22)
To discover biomarkers involved in the pathophysiology of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and to determine whether low-density granulocytes (LDGs) contribute to gene expression signatures in AAV. The source of clinical data and linked biologic specimens was a randomized controlled
Jan Rybniker et al.
Nature communications, 6, 7659-7659 (2015-07-15)
Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, by testing a panel of FDA-approved drugs in
H Dolatshad et al.
Leukemia, 29(5), 1092-1103 (2014-11-28)
The splicing factor SF3B1 is the most commonly mutated gene in the myelodysplastic syndrome (MDS), particularly in patients with refractory anemia with ring sideroblasts (RARS). We investigated the functional effects of SF3B1 disruption in myeloid cell lines: SF3B1 knockdown resulted

